The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...

The FDA has expanded the labeling for Izervay (avacincaptad pegol) to include longer-term administration for geographic ...

Routine evaluation of meibomian glands, starting in childhood, is crucial for identifying and managing this progressive ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAYtm ...

Piper Sandler reaffirmed its Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) with a steady price target of $32.00. The firm's analysis was based on a recent survey of ophthalmologists ...

Even when we think we are holding our gaze perfectly still, our eyes make tiny, involuntary movements. While these ...

Susvimo is now available to U.S. retina specialists and their patients with DME. “Susvimo presents a unique, convenient ...

In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy secondary ... and management of retinal vein occlusion.

Whether it’s something as common as cataracts or more complex conditions like progressive retinal atrophy (PRA), understanding these health risks is key. In this article, we’ll explore the breeds most ...

Securities reiterated its Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) with a stable price target of $30.00, following the company's announcement of its first ex-US approval for Syfovre in ...

Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ... 1 "The approval of SYFOVRE marks a significant milestone for GA patients ...

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular degeneration (nAMD) in eyes with geographic atrophy (GA ... in the CorEvitas ...